公开(公告)号：US09670170B2

公开(公告)日：2017-06-06

申请号：US14776683

申请日：2014-03-14

Applicant: BioElectron Technology Corporation

Inventor： Andrew W. Hinman ,  Dana Davis ,  William D. Shrader

IPC: C07D265/38 ,  C07H17/00 ,  C07D413/10

CPC classification number: C07D265/38 ,  C07D413/10 ,  C07H17/00

Abstract: Disclosed herein are resorufin derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.

公开(公告)号：US20180116978A1

公开(公告)日：2018-05-03

申请号：US15849557

申请日：2017-12-20

Applicant: BIOELECTRON TECHNOLOGY CORPORATION

Inventor： Guy M. Miller ,  William D. Shrader ,  Viktoria Kheifets

IPC: A61K31/122 ,  A61K9/00

CPC classification number: A61K31/122 ,  A61K9/0048 ,  A61K9/0053 ,  A61K31/353 ,  A61K47/44

Abstract: A formulation, comprising an ophthalmically effective amount of one or more tocotrienol quinones, particularly of alpha-tocotrienol quinone is disclosed. Use of a formulation comprising one or more tocotrienol quinones for the prevention, reduction, amelioration or treatment of ophthalmic disorders that are associated with a neurodegenerative or trauma disorder is also discussed. A method of treating or controlling the ocular symptoms associated with neurodegenerative diseases or trauma with a formulation comprising one or more tocotrienol quinones is also discussed. A method of treating or controlling the ocular symptoms associated with mitochondrial myopathies with a formulation comprising one or more tocotrienol quinones is also discussed.

公开(公告)号：US10167251B2

公开(公告)日：2019-01-01

申请号：US15374916

申请日：2016-12-09

Applicant: BioElectron Technology Corporation

Inventor： Orion D. Jankowski ,  Kieron E. Wesson ,  Paul Mollard ,  William D. Shrader

IPC: C07C235/80 ,  C07C235/78 ,  C07C317/28 ,  C07D207/27 ,  C07D211/46 ,  C07D213/40 ,  C07D233/61 ,  C07D295/13 ,  C07D295/192 ,  C07D265/30 ,  C07D311/66 ,  C07D207/26 ,  C07D213/50 ,  C07D295/116 ,  C07D295/185

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, an well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

公开(公告)号：US09868711B2

公开(公告)日：2018-01-16

申请号：US14776688

申请日：2014-03-14

Applicant: BioElectron Technology Corporation

Inventor： Andrew W. Hinman ,  Dana Davis ,  William D. Shrader

IPC: C07D279/20 ,  C07D241/46 ,  C07D279/18

CPC classification number: C07D279/20 ,  C07D241/46 ,  C07D279/18

Abstract: Disclosed herein are phenazine-3-one and phenothiazine-3-one derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.

公开(公告)号：US20190270699A1

公开(公告)日：2019-09-05

申请号：US16228657

申请日：2018-12-20

Applicant: BIOELECTRON TECHNOLOGY CORPORATION

Inventor： Orion D. Jankowski ,  Kieron E. Wesson ,  Paul Mollard ,  William D. Shrader

IPC: C07C235/80 ,  C07C235/78 ,  C07C317/28 ,  A61P25/16 ,  A61P27/00 ,  A61P25/00 ,  C07C235/32 ,  A61P21/00 ,  C07D207/27 ,  C07D295/185 ,  C07D295/116 ,  C07D213/50 ,  C07D207/26 ,  C07D311/66 ,  C07D265/30 ,  C07D295/192 ,  C07D295/13 ,  C07D233/61 ,  C07D213/40 ,  C07D211/46

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinoly)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.